Dr. Jim Omel – The patient / cancer research advocate viewpoint from ASCO 2021 By Adam Barkay|2021-06-15T21:27:35+00:00June 15th, 2021|All, ASCO 2021|Comments Off on Dr. Jim Omel – The patient / cancer research advocate viewpoint from ASCO 2021 Share This Story, Choose Your Platform! FacebookXRedditLinkedInWhatsAppTumblrPinterestVkEmail About the Author: Adam Barkay Related Posts September 13th 2024- Prof. Martin Ellis- Differential Effects of Itacitinib, Fedratinib, and Ruxolitinib in Mouse Models of Hemophagocytic Lymphohistiocytosis September 13th 2024- Prof. Martin Ellis- Differential Effects of Itacitinib, Fedratinib, and Ruxolitinib in Mouse Models of Hemophagocytic Lymphohistiocytosis September 2nd 2024- Prof. Mark Litzow- Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults September 2nd 2024- Prof. Mark Litzow- Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults August 26th 2024- Prof. Olaf Penack- How risky is a second allogeneic stem cell transplantation? August 26th 2024- Prof. Olaf Penack- How risky is a second allogeneic stem cell transplantation? July 22nd 2024- Dr. Kai Rejeski- A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy July 22nd 2024- Dr. Kai Rejeski- A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy July 16th 2024- Prof. Madhav Dhodapkar- Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma July 16th 2024- Prof. Madhav Dhodapkar- Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma
